ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Abstral (formerly branded as Rapinyl), for breakthrough cancer pain. 
Click to view more

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today reveals the results of a year-long study showing that Testosterone Replacement Therapy can significantly improve insulin sensitivity and sexual function in hypogonadal men suffering from Type 2 Diabetes and/or Metabolic Syndrome.
Click to view more

ProStrakan Group plc (LSE: PSK) announces today that, as a result of continuing discussions with the US Food & Drug Administration (FDA), it believes that there are now no outstanding technical questions from the FDA’s review of Sancuso^® other than those which will be dealt with in labeling negotiations. The Company is also issuing an updated timeline for completion of the remaining review process. ProStrakan submitted a New Drug Application (NDA) for Sancuso to the FDA in June 2007.
Click to view more

Galashiels, Scotland and Tokyo, Japan, 23 May, 2008 -- ProStrakan Group plc (LSE: PSK) and JapanBridge K.K. announce today an exclusive licence granted to JapanBridge to develop and commercialise Sancuso^® (granisetron transdermal delivery system) in Japan, China and several other nations throughout South East Asia. 
Click to view more

Galashiels, Scotland, 19 May, 2008 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that it has signed an exclusive licence and supply agreement in Central and Eastern Europe (CEE) and Austria with Torrex Chiesi Pharma GmbH (“Torrex Chiesi”) for the sale of Xomolix.
Click to view more

Galashiels, Scotland, 15 May 2008: ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today issues its Interim Management Statement (IMS) for the period 1 January - 15 May 2008.
Click to view more

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces positive results from the pivotal US clinical program on Fortigel™ for testosterone replacement therapy in hypogonadal men.  Based on these results, ProStrakan expects to re-file Fortigel with the FDA in Q3 2008.
Click to view more

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has received notification from the US Food and Drug Administration (FDA) of its decision to postpone the Action Date under the Prescription Drug User Fee Act (PDUFA) for Sancuso^® by approximately six weeks from early May to mid-June 2008.  Their decision has been taken as a result of the well-publicised resourcing issues currently being experienced by FDA.
Click to view more

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that it has been granted additional key Marketing Authorisations for Droperidol (to be branded Xomolix) in a number of European countries. 
Click to view more

13 March 2008 ProStrakan Group plc (LSE: PSK), the specialty pharmaceutical company, today announces its unaudited Preliminary Results for the year ended 31 December 2007.
Click to view more

ProStrakan Group plc , the international specialty pharmaceutical company, announces that it has received Marketing Authorisation in Sweden for Rapinyl (to be branded Abstral in Sweden).
Click to view more

ProStrakan Group plc today issues a business and trading update for the 12 months ended 31 December, 2007, ahead of the close period preceding the publication of the Group's Preliminary Results, planned for 13 March, 2008.
Click to view more

Galashiels, Scotland, 17^th December, 2007 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that Endo Pharmaceuticals Inc. (“Endo”) has today reported positive results from an interim statistical analysis of its US Phase III, placebo-controlled, double-blind trial of Rapinyl (announcement attached).    Rapinyl is a fast-dissolving tablet for sub-lingual administration of fentanyl intended for the treatment of breakthrough cancer pain.  ProStrakan has in-licensed the exclusive rights to develop and market Rapinyl in Europe from Orexo AB, while Endo has in-licensed the rights for North America.
Click to view more

ProStrakan Group plc, the international specialty pharmaceutical company, announced on 30^th October, 2007 that its co-founder and Chairman, Harry Stratford OBE, had informed the Board of his intention to retire as Chairman at the end of 2007.  The Company also announced that Peter Allen, a Non-Executive Director since 2005, had accepted the Board’s invitation to replace him.   ProStrakan announces that the formal handover took place at the Company’s Board meeting which was held yesterday (6^th December, 2007).
Click to view more

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the launch in the UK of Adcal-D₃ Dissolve 1500mg/400IU Effervescent Tablets – a new, soluble formulation of its market-leading calcium vitamin D supplement, Adcal-D₃.
Click to view more

ProStrakan Group plc (LSE: PSK) today announces that its founder and Chairman, Harry Stratford OBE, has informed the Board of his intention to retire as Chairman at the end of 2007.  Peter Allen, a Non-Executive Director since 2005, has accepted the Board’s invitation to become Chairman from that point.
Click to view more

ProStrakan announces the formation of a strategic alliance with NovaQuest to commercialise ProStrakan's products in the United States of America
Click to view more

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today provides the market with an update on the progress of a number of products undergoing EU approvals processes following yesterday’s EMEA meetings:   ·        Rapinyl EU approval process enters extended phase ·        Droperidol receives EU approval
Click to view more

ProStrakan Group plc, the international pharmaceutical company, today announces its interim results for the six months ended 30 June 2007.
Click to view more

ProStrakan Group plc (LSE: PSK), the specialty pharmaceutical company, today announces the enrolment of the first patients into two pivotal US trials in pursuit of FDA approval for its products: Fortigel (branded Tostran in most of Europe) and Cellegesic (branded Rectogesic in Europe). 
Click to view more

Galashiels, Scotland, 13^th August 2007   ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, today announces that it has signed an exclusive distribution agreement with LG Life Sciences, Ltd. (“LGLS”), a leading pharmaceutical company in South Korea, for Sancuso^®, ProStrakan’s transdermal granisetron patch for the prevention of chemotherapy-induced nausea and vomiting.
Click to view more

ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, announces that it has entered into a joint venture agreement with the Swedish pharmaceutical company, Orexo AB (OMX Midcap: ORX), to collaborate in the marketing and distribution of the current and future product portfolios of both ProStrakan and Orexo in the Nordic countries (Norway, Sweden, Finland, Denmark & Iceland). 
Click to view more

ProStrakan Group plc, the European speciality pharmaceutical company, today issues a business and trading update for the six months ending 30 June, 2007, ahead of the close period preceding the publication of the Group's Interim Results, planned for 12 September, 2007.
Click to view more

ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, today announces the UK launch of Tostran - the latest in a sequence of existing and planned pan-European products.

Click to view more

ProStrakan announces today that it has appointed Paul Garvey as Chief Financial Officer.

Click to view more

Main features: revenue up 22% to £38.5m; gross profit up by 39% to £23m; Sancuso to be filed for regulatory approval during 2007, Tostran and Rectogesic successfully completed EU regulatory approval; Rapinyl and Droperidol submitted for EU approval.
Click to view more

ProStrakan announces today that it has entered into a £50 million debt facility with the initial advance being provided by funds managed by Fortress Investment Group, Morgan Stanley and funds managed by Och-Ziff Capital Management Group.  The Administrative Agent is Morgan Stanley Bank International Limited.
Click to view more

Spreng will join ProStrakan in April from media group SMG plc where he has been Communications Director since 1998.  He will be responsible for strategic communications with the group’s investors, City analysts, business press, specialist press and staff.
Click to view more

ProStrakan announces today the sale of ProSkelia, its Paris-based Drug Discovery unit, to Galapagos NV (“Galapagos” Euronext & London AIM: GLPG) in a transaction valued in total at a maximum of c. €45 million so as to focus its resources entirely on expansion, development and commercialisation of its specialty pharmaceutical product portfolio.
Click to view more

ProStrakan announces today the disposal of its interests in Zindaclin (clindamycin phosphate 1% gel for acne) to Crawford Healthcare Ltd (“Crawford”). 
Click to view more

ProStrakan announces today licensing and distribution agreements with Ferring International Center S.A. (“Ferring”), a subsidiary of Ferring Holding S.A., to distribute Rectogesic™ (glyceryl trinitrate ointment) and Tostran™ (testosterone gel) in various territories in Central and Eastern Europe, Russia and CIS states. 
Click to view more

ProStrakan today announces positive results from the pivotal Phase III programme on Sancuso™,  its patented transdermal delivery system for the treatment of Chemotherapy Induced Nausea and Vomiting (CINV) in patients undergoing multi-day chemotherapy.
Click to view more

ProStrakan today announces that the first milestone has been reached under the exclusive collaboration with Novartis to research, develop and commercialise novel antibodies for bone related diseases. The milestone, relating to intellectual property, triggers a $1m payment.
Click to view more

ProStrakan today announces the completion of the acquisition of expanded rights to two of its leading marketed products, Rectogesic™ and Tostran™ from US-based Cellegy Pharmaceuticals Inc. for a total cash consideration of US$9 million (£4.7 million).  The conditional acquisition was announced on 27 September 2006.
Click to view more

ProStrakan today announces the proposed acquisition of expanded rights to two of its leading marketed products, Rectogesic™ and Tostran™ from US-based Cellegy Pharmaceuticals Inc. for a total cash consideration of US$9 million (£4.7 million).
Click to view more

ProStrakan today announces an exclusive collaboration with Novartis to research, develop and commercialise novel antibodies for bone related diseases.
Click to view more

Main features: gross profit increased 14% to £9.9million; organic sales growth of 24%; Sancuso on track to announce headline results in early 2007; Rapinyl EU filing for marketing approval initiated.
Click to view more

ProStrakan announces today a distribution agreement with Gedeon Richter Ltd, Hungary’s largest pharmaceutical company, to distribute Rapinyl in seven territories in Central and Eastern Europe. 
Click to view more

ProStrakan announces today a conditional placing to raise £11.3m, before expenses. The company also provides a pre-close update for the six months ended June 2006.
Click to view more

ProStrakan announces today an exclusive licence and collaboration agreement with Amgen, to research, develop and commercialise certain of ProStrakan's preclinical compounds for renal disease.
Click to view more

ProStrakan today announces that it has agreed an extension of the geographic rights to two of its leading prescription products, Tostrex and Rectogesic, with its licensing partner, Cellegy Pharmaceuticals Inc. The geographic rights for both Tostrex and Rectogesic will now include Russia and the Commonwealth of Independent States (CIS). 
Click to view more

Trading update statement from today's AGM.
Click to view more

ProStrakan today announces the successful completion of the EU Mutual Recognition Procedure (MRP) for Tostrex. Further launches of the product across Europe now expected in H1 2007.
Click to view more

ProStrakan today unveils its preliminary results for 2005.  Main features: product sales up 47%, gross profit up 69%, EU commercial expansion and progress in R&D pipeline.
Click to view more

ProStrakan has acquired the UK rights to Tabphyn®, a treatment for benign prostatic hyperplasia (BPH) – product to be launched in April.
Click to view more

ProStrakan announces today the successful conclusion of the EU Mutual Recognition Procedure (MRP) for Rectogesic™ ointment for the relief of chronic anal fissure pain, clearing the way for further EU launches of the product.
Click to view more

FDA accepts IND application for Sancuso transdermal patch. Tostrex TIMES2 study gets underway.
Click to view more

ProStrakan Group plc today announces the appointment of Alan Walker to the Board of the Company as an Executive Director. 
Click to view more

Adcal D3, ProStrakan’s UK-marketed calcium/vitamin D supplement used as an adjunct to specific therapy for osteoporosis, now clear market leader in the UK calcium vitamin D market.  
Click to view more

ProStrakan has today acquired the European rights to Rapinyl, a drug in late stage development for the management of breakthrough cancer pain in opioid tolerant patients, from the Swedish pharmaceutical company, Orexo.
Click to view more

ProStrakan Group plc today announces that it has re-negotiated the EU Licence and Distribution Agreement for Rectogesic^® with US-based Cellegy Pharmaceuticals Inc.
Click to view more

ProStrakan has won the 2005 Scotland Technology Fast 50 Award sponsored by Deloitte and the London Stock Exchange. The award recognises the 50 fastest growing technology companies in Scotland, based on percentage turnover growth over five years (2000-2004).
Click to view more

ProStrakan Group plc announces today that its new testosterone replacement therapy, Tostrex® 2% gel, for use in hypogonadal men has been launched onto the Swedish market.
Click to view more

ProStrakan today announces the first set of financial results since IPO in June 2005. Turnover from product sales up 78%.
Click to view more

ProStrakan announces the appointment of Peter Cawdron as Senior Independent Director.
Click to view more

Following ProStrakan's successful IPO, today is the first day of unconditional trading of the company's shares on the London Stock Exchange.  For further details, please click on "Investor Relations".

ProStrakan launches Rectogesic (0.4% topical nitroglycerin ointment) in the UK.

ProStrakan announces that it has acquired the Munich-based pharmaceutical company, APS Pharma GmbH. The acquisition marks a significant expansion of ProStrakan's commercial activities in Germany by providing a portfolio of marketed products supported by an established sales infrastructure.
Click to view more

ProStrakan today announces the appointment of Dr Michael Asbury as a non-executive director.  Michael has spent 30 years in the pharmaceutical industry, culminating in his appointment as Vice President Global Licensing at AstraZeneca from 1999 to 2002.
Click to view more

ProStrakan today announces the appointment of Peter Allen, former CFO and Deputy CEO of Celltech Group plc, to the company’s Board as non-executive director.
Click to view more

ProStrakan Group Limited and Cellegy Pharmaceuticals, Inc. announce that the Medical Products Agency (MPA) in Sweden has approved Tostrex® (testosterone gel) 2% for the treatment of male hypogonadism. Approvals of Tostrex® by the other member states of the European Union will be sought through the Mutual Recognition Procedure.
Click to view more

ProStrakan and Cellegy Pharmaceuticals today announced that they have entered into an exclusive license agreement for the commercialisation of Rectogesic (branded Cellegesic in the US) in Europe. Rectogesic is a 0.4% topical nitroglycerin ointment indicated for the treatment of the pain associated with chronic anal fissures.
Commenting on the deal, Wilson Totten, said: "Having acquired the European rights for Tostrex in July this year, we are delighted to be building on our relationship with Cellegy by acquiring the rights to another of their products."
Click to view more

ProStrakan announces today that it has acquired the Madrid-based pharmaceutical company Elfar S.A. The acquisition marks a significant expansion of ProStrakan's activities in Spain by providing a portfolio of marketed products serviced by an established sales and marketing team in that country. Elfar sells a range of products in the urology and gynaecology therapeutic areas.
Click to view more

Sales of the Group's marketed products continue to demonstrate strong growth. Total group sales in Quarter 3 2004 were £5.4 million. For the first nine months of the year, total sales were over £15 million.

ProStrakan Group Ltd announces the completion of a funding round that has raised £22 million. The funds raised will provide working capital for the company.
Click to view more

Strakan/ProSkelia announce today that Dr Wilson Totten has been appointed CEO with effect from 15th September. Harry Stratford will assume the role of Executive Chairman. Wilson Totten joins the company from Shire plc where he was Group R&D Director.
Also announced today is the closure of the merger between Strakan and Proskelia. The new company will be known as ProStrakan.
Wislon Totten said "I've been following ProStrakan's story for some time now. It is an exciting company with enormous potential and I look forward to being a part of its future growth and success."
Click to view more

Sales of Strakan's marketed products continue to grow strongly. Total group sales for the first 6 months of 2004 were £9.2 million (including OTL sales figures from 26th January, the date of that company's acquisition by Strakan). On an organic basis, sales showed an increase of 108% over the first 6 months of 2003.

A licence agreement has been signed with EpiTan Pharmaceutical Ltd to market and distribute Zindaclin in Australia and New Zealand. In addition, Zindaclin has recently been launched in Belgium, Cyprus, and the Lebanon.

Strakan announced today that it has licensed TostrexTM 2% gel from Cellegy. TostrexTM is a testosterone gel used for the treatment of male hypogonadism which affects up to 7 million men in Europe and Strakan will market the product throughout the EU. Commenting on the deal, Strakan CEO, Harry Stratford said. "Strakan's commercial operations are expanding rapidly throughout Europe. I am confident that TostrexTM will accelerate growth by attracting high demand in a market with major growth potential."
Click to view more

Strakan will join forces with ProSkelia to create a new and exciting specialty pharmaceutical company. The equal merger will exploit the commercial and marketing skills of Strakan, and the R&D expertise of Proskelia. The new company will be headquartered in Scotland, with the primary R&D operation being based at ProSkelia's existing facility in Paris. Harry Stratford, CEO of Strakan, will be CEO of the new company, whilst Prof Roland Baron, founder of ProSkelia, will be President and CSO.
Click to view more